PP
TCRR

PDT Partners’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

PDT Partners’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25,225
Closed -$45K – 959
2022
Q3 		$45K Sell
25,225
-57,529
-70% -$167K 0.01% 812
2022
Q2 		$240K Sell
82,754
-81,182
-50% -$200K 0.02% 792
2022
Q1 		$452K Buy
163,936
+4,985
+3% +$15.7K 0.04% 620
2021
Q4 		$741K Buy
158,951
+133,532
+525% +$835K 0.06% 431
2021
Q3 		$216K Buy
+25,419
New +$359K 0.02% 676

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

PDT Partners's TCRR Position: Q4 2022 in Review

PDT Partners sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2022, closing a stake of 25,225 shares — an estimated $45K sold.

PDT Partners first reported a position in TCRR in Q3 2021 and held it in 5 quarters. The position peaked at $741K in Q4 2021. 63 funds tracked by Wall St. Rank hold TCRR as of Q4 2022.

  • PDT Partners reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • PDT Partners sold 25,225 TCR2 Therapeutics Inc. Common Stock shares in Q4 2022, an estimated $45K.
  • PDT Partners first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2021 and held it in 5 quarters.
  • PDT Partners's TCR2 Therapeutics Inc. Common Stock position peaked at $741K in Q4 2021.
  • 63 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2022.

Based on PDT Partners's 13F filing for Q4 2022, filed 14 Feb 2023.